Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.
作者信息
Osborne R J, Malik S T, Slevin M L, Harvey V J, Spona J, Salzer H, Williams C J
机构信息
ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
出版信息
Br J Cancer. 1988 Jan;57(1):115-6. doi: 10.1038/bjc.1988.22.
Abstract
摘要
相似文献
1
Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.他莫昔芬治疗难治性卵巢癌：负荷剂量方案的应用。
Br J Cancer. 1988 Jan;57(1):115-6. doi: 10.1038/bjc.1988.22.
2
Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.晚期乳腺癌患者在负荷剂量后及稳态水平时他莫昔芬及其代谢物的血清和尿液水平。
Cancer Chemother Pharmacol. 1998;42(6):512-4. doi: 10.1007/s002800050854.
3
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).吉非替尼联合他莫昔芬用于铂类-紫杉烷类基础治疗难治或耐药的卵巢癌患者——AGO卵巢癌研究组的一项II期试验（AGO-OVAR 2.6）
Gynecol Oncol. 2007 Apr;105(1):132-7. doi: 10.1016/j.ygyno.2006.10.053. Epub 2006 Dec 11.
4
A phase II study of tamoxifen in ovarian cancer.他莫昔芬治疗卵巢癌的II期研究。
Eur J Cancer Clin Oncol. 1986 Mar;22(3):309-12. doi: 10.1016/0277-5379(86)90396-2.
5
Tamoxifen therapy for advanced ovarian cancer.他莫昔芬治疗晚期卵巢癌
Obstet Gynecol. 1982 May;59(5):583-8.
6
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
Gynecol Oncol. 1996 Jul;62(1):4-6. doi: 10.1006/gyno.1996.0181.
7
Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.他莫昔芬在乳腺癌患者中的临床药理学：传统给药方案与负荷剂量方案的比较
Cancer Treat Rep. 1980 Jun-Jul;64(6-7):765-73.
8
9
[Clinical evaluation of tamoxifen for advanced and recurrent breast cancer (author's transl)].他莫昔芬治疗晚期和复发性乳腺癌的临床评估（作者译）
Horumon To Rinsho. 1980 Apr;28(4):425-36.
10
Tamoxifen therapy of epithelial ovarian cancer.他莫昔芬治疗上皮性卵巢癌
Obstet Gynecol. 1985 Oct;66(4):575-8.
引用本文的文献
1
Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).卵巢癌的激素治疗：强调机制与应用（综述）。
Oncol Rep. 2021 Oct;46(4). doi: 10.3892/or.2021.8174. Epub 2021 Aug 26.
2
New insights on the role of hormonal therapy in ovarian cancer.激素疗法在卵巢癌中作用的新见解。
Steroids. 2013 Jun;78(6):530-7. doi: 10.1016/j.steroids.2013.01.008. Epub 2013 Feb 8.
3
Hormone response in ovarian cancer: time to reconsider as a clinical target?卵巢癌中的激素反应：是否应重新考虑将其作为临床靶点？
Endocr Relat Cancer. 2012 Nov 9;19(6):R255-79. doi: 10.1530/ERC-12-0175. Print 2012 Dec.
4
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature.抗雌激素疗法治疗复发性卵巢癌获28个月疾病稳定：一例病例报告及文献综述
Arch Oncol. 2010;18(1-2):32-35. doi: 10.2298/AOO1002032K.
5
Tamoxifen for relapse of ovarian cancer.他莫昔芬用于卵巢癌复发的治疗。
Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD001034. doi: 10.1002/14651858.CD001034.pub2.
6
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.雌激素受体表达以及雌激素和他莫昔芬对人卵巢癌细胞系生长的影响。
Br J Cancer. 1990 Aug;62(2):213-6. doi: 10.1038/bjc.1990.263.
7
The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.醋酸环丙孕酮在晚期卵巢癌中的临床活性。伦敦妇科肿瘤学组研究。
Br J Cancer. 1991 Nov;64(5):973-4. doi: 10.1038/bjc.1991.440.
本文引用的文献
1
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
2
Advanced ovarian carcinoma: response to antiestrogen therapy.晚期卵巢癌：抗雌激素治疗的反应
Cancer. 1981 Dec 1;48(11):2368-70. doi: 10.1002/1097-0142(19811201)48:11<2368::aid-cncr2820481105>3.0.co;2-j.
3
Androgen and oestrogen binding in cytosols of human ovarian tumours.
J Endocrinol. 1981 Sep;90(3):421-31. doi: 10.1677/joe.0.0900421.
4
Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.他莫昔芬（诺瓦得士）治疗——转移性乳腺癌患者先给予负荷剂量后给予维持剂量的理论依据。
Cancer Chemother Pharmacol. 1982 Dec;10(1):33-5. doi: 10.1007/BF00257234.
5
Tamoxifen therapy for advanced ovarian cancer.他莫昔芬治疗晚期卵巢癌
Obstet Gynecol. 1982 May;59(5):583-8.
6
Peripheral venous concentrations of oestrogens in postmenopausal women with ovarian cancer.患有卵巢癌的绝经后女性外周静脉血中雌激素的浓度。
Br J Obstet Gynaecol. 1982 Jan;89(1):84-6. doi: 10.1111/j.1471-0528.1982.tb04643.x.
7
Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors.孕酮作为“非内分泌性”卵巢恶性肿瘤的一种可能的肿瘤标志物。
Gynecol Oncol. 1983 Aug;16(1):129-38. doi: 10.1016/0090-8258(83)90018-5.
8
Tamoxifen therapy of epithelial ovarian cancer.他莫昔芬治疗上皮性卵巢癌
Obstet Gynecol. 1985 Oct;66(4):575-8.
9
Estrogen and progesterone receptors in epithelial ovarian malignancies.上皮性卵巢恶性肿瘤中的雌激素和孕激素受体
Gynecol Oncol. 1986 Feb;23(2):176-82. doi: 10.1016/0090-8258(86)90221-0.
10
A phase II study of tamoxifen in ovarian cancer.他莫昔芬治疗卵巢癌的II期研究。
Eur J Cancer Clin Oncol. 1986 Mar;22(3):309-12. doi: 10.1016/0277-5379(86)90396-2.
Zotero 插件